Arlington Partners’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$165K Sell
650
-338
-34% -$78.8K 0.3% 60
2026
Q1
$242K Buy
+988
New +$230K 0.48% 23
2025
Q4
Sell
-29,010
Closed -$5.38M 30
2025
Q3
$5.38M Hold
29,010
1.86% 9
2025
Q2
$4.43M Buy
29,010
+2,882
+11% +$443K 1.63% 34
2025
Q1
$4.33M Buy
26,128
+18,641
+249% +$2.92M 1.7% 29
2024
Q4
$1.08M Sell
7,487
-19,193
-72% -$2.97M 0.42% 54
2024
Q3
$4.32M Buy
26,680
+5,334
+25% +$850K 1.69% 23
2024
Q2
$3.12M Buy
21,346
+2,423
+13% +$360K 1.55% 46
2024
Q1
$2.99M Buy
18,923
+4,930
+35% +$785K 1.52% 43
2023
Q4
$2.19M Sell
13,993
-4,810
-26% -$738K 0.63% 54
2023
Q3
$2.93M Buy
18,803
+1,268
+7% +$209K 1.2% 18
2023
Q2
$2.9M Buy
17,535
+995
+6% +$161K 0.45% 24
2023
Q1
$2.56M Sell
16,540
-202
-1% -$32.6K 0.36% 22
2022
Q4
$2.96M Buy
16,742
+116
+0.7% +$20K 0.47% 20
2022
Q3
$2.72M Buy
16,626
+851
+5% +$144K 1.09% 19
2022
Q2
$2.8M Sell
15,775
-1,750
-10% -$312K 0.93% 19
2022
Q1
$3.11M Sell
17,525
-2,191
-11% -$373K 0.88% 20
2021
Q4
$3.37M Buy
19,716
+1,308
+7% +$214K 0.91% 21
2021
Q3
$2.97M Buy
18,408
+1,956
+12% +$334K 0.86% 27
2021
Q2
$2.71M Buy
16,452
+1,631
+11% +$270K 0.94% 26
2021
Q1
$2.44M Buy
14,821
+2,699
+22% +$437K 0.89% 24
2020
Q4
$1.91M Buy
12,122
+2,144
+21% +$316K 0.88% 25
2020
Q3
$1.49M Buy
9,978
+73
+0.7% +$10.8K 0.81% 31
2020
Q2
$1.39M Buy
9,905
+1,065
+12% +$155K 0.78% 33
2020
Q1
$1.16M Buy
8,840
+6,050
+217% +$858K 0.6% 31
2019
Q4
$407K Buy
2,790
+80
+3% +$10.9K 0.25% 35
2019
Q3
$351K Sell
2,710
-5,976
-69% -$787K 0.22% 32
2019
Q2
$1.21M Buy
8,686
+6,226
+253% +$862K 0.54% 39
2019
Q1
$344K Sell
2,460
-5,940
-71% -$796K 0.25% 35
2018
Q4
$1.08M Buy
8,400
+245
+3% +$34.2K 0.71% 27
2018
Q3
$1.13M Hold
8,155
0.79% 28
2018
Q2
$990K Sell
8,155
-14
-0.2% -$1.75K 0.94% 25
2018
Q1
$1.05M Buy
8,169
+814
+11% +$110K 0.99% 23
2017
Q4
$1.03M Buy
+7,355
New +$1.02M 1.06% 27

Other funds holding JNJ

Arlington Partners's JNJ Position: Q2 2026 in Review

Arlington Partners reduced its Johnson & Johnson (JNJ) stake by 34% in Q2 2026, selling an estimated $78.8K and leaving 650 shares worth $165K. The position accounts for 0.3% of the portfolio, ranked #60.

Arlington Partners first reported a position in JNJ in Q4 2017 and has held it in 34 quarters since. The position peaked at $5.38M in Q3 2025. 899 funds tracked by Wall St. Rank hold JNJ as of Q2 2026.

  • Arlington Partners held 650 shares of Johnson & Johnson worth $165K as of Q2 2026.
  • Arlington Partners sold 338 Johnson & Johnson shares in Q2 2026, an estimated $78.8K.
  • Johnson & Johnson made up 0.3% of Arlington Partners's portfolio in Q2 2026, its #60 holding.
  • Arlington Partners first reported a position in Johnson & Johnson in Q4 2017 and has held it in 34 quarters since.
  • Arlington Partners's Johnson & Johnson position peaked at $5.38M in Q3 2025.
  • 899 funds tracked by Wall St. Rank held Johnson & Johnson as of Q2 2026.

Based on Arlington Partners's 13F filing for Q2 2026, filed 7 Jul 2026.